FDA warns consumers to be on lookout for fake Ozempic (NYSE:NVO)

CR/iStock via Getty Images

The FDA is alerting consumers to be on the lookout for fake versions of the GLP-1 drug Ozempic, a diabetes drug that has become increasingly popular for weight loss.

The agency said in a warning posted on its website Thursday that it has seized thousands of units of counterfeit Ozempic, also known as semaglutide. The FDA advises wholesalers, pharmacies, patients and healthcare providers not to distribute or use Ozempic products carry the lot number NAR0074 and serial number 430834149057.

The FDA said it has received reports of five adverse events connected to the counterfeit products, but they were consistent with common adverse reactions to genuine Ozempic. No serious events have been reported, it added.

Ozempic is approved for the treatment of diabetes. The drug is also approved and marketed for weight loss under the name Wegovy. Both drugs, which are injected, are sold by Danish drugmaker Novo Nordisk (NVO).

The FDA and Novo Nordisk have been testing the seized products for identity, quality and safety. The agency warned that the products have also been found to have counterfeit components such as needles, labeling, accompanying information and cartons. It cautioned that the counterfeit needles may not be sterile.

The agency advised patients to only obtain Ozempic with a valid prescription through a state-licensed pharmacy.

Source link